Research programme: autologous stem cell therapies - BrainStorm Cell Therapeutics

Drug Profile

Research programme: autologous stem cell therapies - BrainStorm Cell Therapeutics

Alternative Names: NurOwn™ program two

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 30 Nov 2015 BrainStorm Cell Therapeutics receives $US7 35 000 grant from Israel's Office of the Chief Scientist (OCS) in the Ministry of Economy for NurOwn™ development in Neurodegenerative disorders
  • 02 Sep 2014 Early research in Neurodegenerative disorders in Israel is ongoing (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top